DNA/RNA Synthesis Inhibitor

Napropamide (Standard) (Napropamid (Standard)) is the analytical standard of Napropamide (HY-B1972). This product is intended for research and analytical applications. Napropamide (Napropamid) is an amide herbicide that can be used to control weeds in fruits, vegetables, tobacco, and ornamental plants. Napropamide mainly exerts its effect by inhibiting DNA synthesis and cell division. Napropamide has moderate to high persistence in the field, with a half-life of 24-131 days, and is prone to photodegradation.

p21PBP, a 20 amino-acid peptide, is an inhibitor of DNA replication. p21PBP specifically binds to purified proliferating cell nuclear antigen (PCNA) in tumour cell extracts. p21PBP is promising for research of cancers.

WRN-IN-25 is an allosteric Werner syndrome helicase (WRN) inhibitor with an IC₅₀ of 15 nM and a K_d of 54 nM. WRN-IN-25 induces DNA damage, reduces cell viability, and exhibits synthetic lethality in WRN-driven high microsatellite instability cancer cells. WRN-IN-25 can be used in research related to microsatellite instability cancers.

S-(N-PhenethylthiocarbaMoyl)-L-cysteine (PEITC-Cys), an anticarcinogenic agent, has antileukemic activity. S-(N-PhenethylthiocarbaMoyl)-L-cysteine inhibits DNA synthesis in HL60 cells. S-(N-PhenethylthiocarbaMoyl)-L-cysteine is a P450 inhibitor.

(rel)-Oxaliplatin is a DNA synthesis inhibitor. (rel)-Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. (rel)-Oxaliplatin can be used for cancer research.

DHX9-IN-8 (Compound 6) is a RNA helicase DHX9 inhibitor, with an EC₅₀ of 3.4 μM in DHX9 cellular target engagement. Used in cancer research.

DHX9-IN-14 (161) is a RNA helicase DHX9 inhibitor, with an EC₅₀ of 3.4 μM in DHX9 cellular target engagement. Used in cancer research.

Fidaxomicin-d₆ (OPT-80-d₆) is the deuterium labeled Fidaxomicin (HY-17580). Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC₉₀=0.12 μg/mL). Fidaxomicin can be used for Clostridium difficile infection (CDI) research.

(E)-3-AP is the E configuration of 3-AP. 3-AP is a potent ribonucleotide reductase inhibitor. 3-AP shows anti-proliferative activity. 3-AP shows anticancer activity in L1210 leukemia model. 3-AP inhibits RR activity and DNA synthesis.

NK-611 (VP 19) is an epipodophyllotoxin derivative. NK-611 induces DNA double-strand breaks by inhibiting topoisomerase II (IC₅₀ = 56 μM). NK-611 does not inhibit microtubule polymerization, thus avoiding the side effects of the parent compound, Podofilox (HY-15552). NK-611 exhibits broad-spectrum antitumor activity and demonstrates potent efficacy in in vivo models of leukemia. NK-611 can be used in cancer research.

2’-O-Methyl-5-iodouridine (5-Iodo-2'-O-methyluridine) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.

LB80317 is an active metabolite of LB80380 and suppresses the DNA synthesis of HBV with an EC₅₀ of 0.5 μM. LB80317 has antiviral effect and has the potential for chronic hepatitis B treatment.

1-Benzyl-4-(bromomethyl)-1H-1,2,3-triazole is a bromomethyl derivative that inhibits DNA synthesis in tumor cells and promotes the release of radioactivity from labeled nucleic acids. 1-Benzyl-4-(bromomethyl)-1H-1,2,3-triazole inhibits the growth of cancer cells in vitro with an ED₅₀ of 2 μg/mL. It can be used in cervical cancer-related research.

T-2513 is a selective topoisomerase I inhibitor. T-2513 binds covalently to and stabilizes the topoisomerase I-DNA complex and inhibits DNA replication and RNA synthesis, ultimately leading to cell death.

Cidofovir-¹³C,¹⁵N₂ disodium (GS 0504-¹³C,¹⁵N₂ disodium) is the ¹³C- and ¹⁵N-labeled Cidofovir disodium (HY-167911). Cidofovir sodium is an acyclic monophosphate nucleotide analogue and CMV inhibitor with antiviral activity. Cidofovir sodium inhibits cytomegalovirus (CMV) replication by selectively inhibiting viral DNA polymerase. Cidofovir sodium induces apoptosis and can be used in studies of AIDS cytomegalovirus retinitis, herpes, and cancer. Cidofovir sodium also has anti-orthopoxvirus and anti-variola activities.

Topoisomerase I-IN-18, a derivative of Thiosemicarbazide (HY-Y0032), is a Topoisomerase I inhibitor. Topoisomerase I-IN-18 can disrupt DNA synthesis and transcription. Topoisomerase I-IN-18 inhibits tumor cell proliferation by inducing S-phase cell cycle arrest. Topoisomerase I-IN-18 can enhance mitochondria-mediated apoptosis, suppress cell migration, and increase intracellular Reactive Oxygen Species (ROS) levels. Topoisomerase I-IN-18 can increase p53 protein expression, γH2AX phosphorylation, upregulate Bax expression, downregulate Bcl-2 expression, and activate the caspase cascade. Topoisomerase I-IN-18 can be used for the study of lung cancer.

Anticancer agent 262 (compound 3h) is a DNA intercalating anticancer agent, with an IC₅₀ of 5.7 µM against A549 cancer cells.

ART558 (GMP) is ART558 (HY-141520) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. ART558 is a potent, selective and allosteric DNA polymerase theta (Polθ) inhibitor (IC₅₀=7.9 nM). ART558 elicits BRCA-gene synthetic lethality and DNA damage. ART558 can be used for the research of cancer, such as breast cancer.

PROTAC CDK9 degrader-11 is an orally active, selective CDK9 PROTAC degrader with a DC₅₀ of 1.09 nM. PROTAC CDK9 degrader-11 recruits CRBN to form a ternary complex and degrades CDK9 via the ubiquitin-proteasome pathway, thereby inhibiting RNA polymerase II phosphorylation and downregulating the expression of anti-apoptotic and pro-oncogenic genes, ultimately inducing apoptosis. PROTAC CDK9 degrader-11 is suitable for research on small-cell lung cancer (SCLC).

Simeprevir-¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses.